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creativecommons.org/licenses/by-nc-nd/Abstract Background: Dual HER2-inhibition combined with neoadjuvant chemotherapy al-
lows increased pathological complete response (pCR) rate. However, with the addition of new
agents, there is a growing need to select patients to minimise overtreatment. Herein, we eval-
uated the 41-gene classifier TRAR to predict pCR to anti-HER2 therapies in the NeoALTTO
trial.
Patients and methods: Gene expression data were obtained using RNA from 226 pretreatment
tumour biopsies. Logistic regression analysis and the area under the receiver operating char-
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Results: TRAR levels were associated with pCR (odds ratio, OR: 0.25, 95% confidence inter-
val, CI: 0.15e0.42). The ROC analysis showed AUC values of 0.73 (95% CI: 0.67e0.80) over-
all; 0.70 (0.59e0.81) and 0.71 (0.62e0.80) for positive and negative oestrogen receptor
cases and 0.74 (0.60e0.88), 0.76 (0.65e0.87) and 0.71 (0.59e0.83) for trastuzumab,
lapatinib and combined treatment arms, respectively. TRAR provided reliable predictive in-
formation beyond established clinicopathological variables (OR: 0.26, 95% CI: 0.14e0.47).
Furthermore, addition of TRAR to these variables provided greater predictive capability than
the addition of PAM50: AUC 0.78 (0.72e0.84) versus 0.74 (0.67e0.81), p Z 0.04.
Conclusion: TRAR represents a promising tool to refine the ability to identify patients sensi-
tive to anti-HER2 (including trastuzumab-only)-based therapy and eligible for de-escalated
treatment strategies.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The HER2 gene is amplified and/or overexpressed in
approximately 20% of breast cancer (BC) cases [1] and
has been associated with aggressive disease and poor
prognosis [2]. The introduction of dual anti-HER2
combinations, i.e. trastuzumab (T) plus (þ) lapatinib
(L) or T þ pertuzumab (P), improved the clinical
outcome of patients in this subgroup. T þ L in the
NeoALTTO trial showed higher pathological complete
response (pCR) compared with either T or L with
paclitaxel (51.3% versus 29.5% or 24.7%, respectively;
p < 0.01 for both) [3]. Again, in the neoadjuvant setting,
the Neosphere study reported increased pCR by adding
P to T with docetaxel (45.8% versus 29.0%, p Z 0.014)
[4]. The development of strategies with dual anti-HER2
combinations was paralleled by the growing need to
select patients for optimal treatment. When the results
of the ALTTO study were published [5], it came out as a
proof of concept that the simple combination of
potentially active agents, i.e. L to standard adjuvant T-
based therapy, does not necessarily yield survival gain.
Furthermore, undoubtedly effective dual anti-HER2
combination may be unnecessary in patients who
already benefit from a single agent [6]. Hence, finding
positive predictive marker(s) of response could have
huge impact towards de-escalating strategies in terms of
single agent versus dual blockade and/or duration of
chemotherapy. Different studies have failed to demon-
strate that a single biomarker can identify patients who
differentially respond to T [7], possibly because of the
multifaceted drug mechanism of action [8]. Moreover,
the recently reported interplay between primary tumour
HER2-dependence and immune system [9] supports the
concept that HER2 overexpression per se is not suffi-
cient to define anti-HER2 responders.
At Fondazione IRCCS Istituto Nazionale dei
TumoridMilano (INT), we developed the 41-gene
classifier TRAR, which is able to identify HER2-posi-
tive BC patients with differential risk of relapse upontreatment with adjuvant T [10] and provides reliable
predictive information over established clinical factors
in the neo-adjuvant setting [10,11]. The discriminatory
capability of TRAR stands on its unique feature of
including both HER2- and oestrogen receptor (ER)-
related genes and to split tumours according to their
immune infiltration characteristics [10]. Herein, we took
advantage of the unique opportunity to profile RNA
from pretreatment fresh tumour biopsies obtained from
NeoALTTO patients, to assess whether TRAR is asso-
ciated with pCR to single or dual HER2-targeted
therapies.
2. Methods
2.1. Patients
The results of the multicentre randomised phase III
NeoALTTO trial (NCT00553358) have already been
published [3]. Briefly, patients with HER2-positive BC
were randomised to preoperative L, T or their combi-
nation for 6 weeks followed by the addition of paclitaxel
for further 12 weeks. After surgery, patients continued
with three cycles of fluorouracil, epirubicin and cyclo-
phosphamide followed by the same HER2-targeted
therapy administered in the preoperative setting to
complete 1 year of treatment. The primary end-point of
the study, which was conducted in accordance with the
Declaration of Helsinki, was pCR in the breast. Written
informed consent was obtained from all patients at
study entry, which also covered future biomarker
research.
2.2. Gene expression profiling analysis
RNA was obtained from snap frozen core biopsies of
primary tumours before the initiation of neoadjuvant
therapy as already reported [12]. RNA samples stored at
the central biobank of Vall d’Hebron University Hos-
pital, Barcelona, were shipped to INT. RNA
Fig. 1. Flow diagram of patients and samples included in the
analysis.
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photometer (NanoDrop),and RNA quality was checked
using TapeStation 2200 (Agilent) and the RNA integrity
number. Gene expression data were generated using
HumanHT12_v4 beadchips (Illumina, San Diego, CA),
as per protocol and detailed in the Supplementary
methods.
The 41-gene classifier TRAR (Supplementary Table
S1) was computed as previously described [10]. Be-
sides, gene expressionebased biomarkers including
ERBB2 and ESR1, the research-based PAM50 subtype
predictor [13], immune metagenes [14] and proliferation
signatures [15] were also evaluated (Supplementary
methods).
Gene set enrichment analysis (GSEA) was per-
formed using ‘fgsea’ function from R package. The
enrichment score values were calculated according to
the gene list ordered on the bases of their fold change.
The predefined gene sets from Gene Ontology (GO)
annotation (http://bioinf.wehi.edu.au/software/
MSigDB/index.html), including categories of
molecular function, cellular component or biological
process and KEGG pathways, were analysed. Then,
the collapse pathways function was used to select
only independent pathways from the list of
statistically significant enriched pathways (i.e. false
discovery rate [FDR], p-value<0.05).
2.3. Statistical analysis
The association of TRAR levels, measured on a
continuous scale, with pCR as well as with other cate-
gorical clinicopathological variables was evaluated by
resorting to the non-parametric KruskaleWallis test.
The strength of the association was assessed by the
Spearman correlation coefficient (rs) and its 95% confi-
dence interval (95% CI) [16]. Univariate logistic regres-
sion analysis was implemented for each variable of
interest to estimate the odds ratio (OR) and its 95% CI
[17]. The relationship between continuous variables and
pCR probability was investigated by resorting to a
regression model based on restricted cubic splines [18].
The predictive performance of TRAR with respect to
pCR was further evaluated by resorting to a multivar-
iate logistic regression model by taking into account
treatment arm (T-arm as reference), age (continuous),
tumour size (5 cm versus >5 cm), nodal (N0/1 versus
other) and ER status (negative versus positive). The
discriminatory capability of each model was evaluated
in terms of area under the receiver operating charac-
teristic (ROC) curve (AUC) and the corresponding 95%
CI [19]. The non-parametric approach of DeLong and
Clarke-Pearson [20] was used to compare the discrimi-
natory capability of TRAR with respect to PAM50.
Finally, TRAR was dichotomised according to the cut-
off value identified by maximising the Youden index
from the univariate ROC curve. Within each of theobtained subgroups, i.e. TRAR-low and TRAR-high, a
list of differentially expressed genes between patients
achieving or not pCR was identified by resorting to
KruskaleWallis test. All statistical analyses were carried
out with the SAS (version 9.2.; SAS Institute, Inc., Cary,
NC) and R software by adopting a significance level of
a Z 0.05.3. Results
3.1. Patient characteristics
Overall, 455 patients were enrolled in the NeoALTTO
trial; from 226 of them (49.6%), gene expression data
were obtained for the purpose of the present analysis
(Fig. 1).
Specifically, RNA of enough quality and quantity
was obtained for 232 patients and processed for micro-
array hybridisation. Six samples out of 232 did not pass
the quality-control procedures. Baseline characteristics
of patients evaluated for the present study, hereinafter
called TRAR cohort, were superimposable with those of
the whole NeoALTTO trial (Supplementary Table S2).3.2. Evaluation of TRAR predictive capability
TRAR resulted significantly associated with ER status
(p < 0.001) and tumour size (p Z 0.005)
(Supplementary Fig. S1). No statistically significant as-
sociation was observed between TRAR and age, nodal
status and treatment arm (Supplementary Fig. S1). Of
the 226 evaluable cases, 80 (35%) achieved a pCR, spe-
cifically following L (nZ 21, 27%), T (nZ 19, 28%) and
their combination (n Z 40, 51%) plus paclitaxel.
Table 1
Association of TRAR and clinicopathological variables with patho-
logical complete response (pCR): Univariate and multivariate logistic
regression model.
Variables Univariate
OR (95% CI)
Multivariate
OR (95% CI)
TRAR score 0.25 (0.15e0.42) 0.26 (0.14e0.47)
Treatment
L versus T 0.95 (0.46e1.97) 0.95 (0.43e2.09)
LþT versus T 2.77 (1.39e5.52) 3.08 (1.45e6.58)
ER status
Neg versus Pos 2.62 (1.46e4.69) 1.25 (0.61e2.57)
Age 0.99 (0.96e1.01)
Tumour size
5 versus > 5 0.91 (0.52e1.59)
Nodal status
N0/1 versus  N2 0.62 (0.31e1.26)
The bold values correspond to statistically significant odds ratio
OR, odds ratio; CI, confidence interval; L, lapatinib; T, trastuzumab;
ER, oestrogen receptor.
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without pCR (p < 0.001). Specifically, the median levels
of TRAR were lower in patients achieving pCR
(Fig. 2A). Univariate logistic regression analysis
(Table 1) showed that TRAR levels were associated with
pCR (OR: 0.25, 95% CI: 0.15e0.42) with an AUC of
0.73 (95% CI: 0.67e0.80) (Fig. 2B). The predictive value
of TRAR was confirmed in both ER positive and
negative cases, AUC 0.70 (95% CI: 0.59e0.81) and
AUC 0.71 (95% CI: 0.62e0.80), respectively, and in all
treatment arms: AUC 0.76 (95% CI: 0.65e0.87), AUC
0.74 (95% CI: 0.60e0.88) and AUC 0.71 (95% CI:
0.59e0.83) in L, T and their combination, respectively
(Supplementary Fig. S2).
3.3. Multivariate analyses
In the TRAR cohort, the main clinicopathological
drivers of pCR were ER status and treatment arm;
TRAR retained its predictive role when considered
together with these variables (OR: 0.26, 95% CI:
0.14e0.47) (Table 1). Gene expression data including
ERBB2, ESR1, PAM50 and the MSK proliferation
molecular score were significantly associated with pCR,
in both univariate and multivariate analysis
(Supplementary Table S3). Conversely, the immune-cell
signatures, i.e. haematopoietic cell kinase (HCK),
interferon (IFN), lymphocyte-specific kinase (LCK),
MHC-II and STAT1 metagenes [14], were found not
associated with pCR (Supplementary Table S4). As
shown in Supplementary Fig. S3, TRAR correlated with
ERBB2 (rs:- 0.70, 95% CI: 0.76 to 0.63), ESR1 (rs:
0.76, 95% CI: 0.71e0.81) and PAM50 (p < 0.001), even
though TRAR seems to better explain the distributionFig. 2. Distribution of TRAR score according to pathological complete re
(ROC) curve in the TRAR cohort (n[226). (A) The box-plots show t
disease (No pCR) in the overall analysed cohort (n Z 226). Shown a
median (horizontal line) and the extreme values (whiskers). (B) ROC
modelling the probability of pCR. The reference line is in grey, a ROC c
is no better than chance.of pCR in the study population with respect to the other
tested gene expressionebased indices (Fig. 3). Of note, a
subset of TRAR-low tumours was not classified as
HER2-enriched (HER2-E) (Supplementary Fig. S3c).
Finally, TRAR did not correlate (rs Z 0.19, 95% CI:
0.32 to 0.05) but rather provided additional predic-
tive capability in combination with the proliferation
score MSK (Fig. 3).
TRAR retained its significant association with pCR
in a multivariate regression model containing age,
treatment arm, ER status, tumour size and nodal status
(OR 0.25, 95% CI 0.13e0.46, p < 0.0001). Furthermore,
the addition of these variables to TRAR provided
significantly higher predictive capability as compared
with their addition to PAM50 (dichotomised as HER2-sponse (pCR) and the corresponding receiver operating characteristic
he distribution of TRAR score in patients with pCR and residual
re the 25th and the 75th percentiles of the distribution (box), the
curve derived from the univariate logistic analysis of TRAR score
urve lying on the reference line reflects that the performance of test
Fig. 3. Predictive performance of TRAR and the other gene
expression based indices in the TRAR cohort (n[226). Blue circles
and red squares indicate the area under the receiver operating
characteristic (ROC) curves (AUC) obtained from the univari-
ate (blue) and multivariate (red) model, respectively, that in-
cludes oestrogen receptor status and treatment arm. Horizontal
bars indicate the 95% confidence interval of the AUC. Value of
AUC is expected to be 0.5 in absence of predictive capability,
whereas it tends to be 1.00 in the case of high predictive ca-
pacity. To aid the reader to interpret the value of this statistic,
we suggest that values between 0.6 and 0.7 be considered as
indicating a weak predictive capacity, values between 0.71 and
0.8 a satisfactory predictive capacity and values > 0.8 a good
predictive capacity. (For interpretation of the references to
colour in this figure legend, the reader is referred to the Web
version of this article.)
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0.74 (0.67e0.81), p Z 0.04 (Fig. 4).
3.4. Identification of genes associated with pCR in TRAR-
low and TRAR-high BC
We next examined differences in gene expression in
patients with and without pCR within the subgroups
defined by the Youden cut-off as TRAR-low (n Z 108,
of whom 57 pCR) and TRAR-high (n Z 118, of whom
23 pCR). By considering unadjusted p-value < 0.05,
1337 and 734 differentially expressed genes (DEGs) were
identified in TRAR-low and TRAR-high subgroups,
respectively. Supplementary Table S5 reports top DEGs
(unadjusted p-value < 0.01 and fold change > 2 or <
0.5).
By GSEA, several gene sets were significantly (FDR
< 0.05) and positively enriched (enrichment score,
ES > 0) in cases achieving pCR, both in TRAR-low and
TRAR-high cases, but none in cases with residual dis-
ease. To identify the pathways, which had the most
significant involvement with the genes identified, DEGs
were submitted into the GO and KEGG pathway
analysis. The upregulated DEGs were enriched in GOterms associated with immune response, cell cycle and
response to stimuli and metabolism (Supplementary
Table S6). KEGG analysis identified no statistically
significantly enriched pathways in TRAR-high sub-
group; whereas, upregulated DEGs were significantly
enriched in immune response and cell cycle pathways in
TRAR-low subgroup (Supplementary Table S7).
Therefore, we finally evaluated the predictive capability
of the immune metagenes HCK, IFN, LCK, MHC-II
and STAT1 and the proliferation molecular score
MSK within each TRAR subgroup. HCK, STAT1 and
MSK were statistically significant associated with pCR
(Table 2) in the TRAR-low subgroup, whilst none of
these signatures was associated with pCR in TRAR-
high cases.4. Discussion
Achievement of pCR after neoadjuvant therapy has
emerged as a challenging goal, because pCR is associ-
ated with lower recurrence risk and higher overall sur-
vival in BC patients [21,22]. Though HER2
overexpression/amplification is widely accepted as a
biomarker to assign anti-HER2 agents [23], it is not
sufficient to recapitulate the heterogeneity of treatment
response [24]. The establishment of predictive bio-
markers for single or dual HER2-targeted therapy is
therefore of utmost importance to personalise the ‘right’
amount of therapy, because proper patients’ selection
can avoid toxic/expensive drugs or, conversely, support
the use of therapeutic escalation strategies.
Our results demonstrate that the TRAR classifier is
able to identify HER2 positive BC patients likely to
respond to either L, T or their combination plus pacli-
taxel. A significant association was found for TRAR
and the levels of ERBB2 and ESR1. This is not sur-
prising, as TRAR was constructed based on the
expression of 41 genes, including ERBB2 and ESR1. It is
well known that ER may act as a direct regulator of
ERBB2 transcription [25] and that HER2 can in turn
directly control ER genomic activity [26]. The predictive
value of these latter genes has emerged in neoadjuvant
trials using either T or its combination with L [12] or P
[27,28]. However, we showed that TRAR has an added
predictive value as compared with these single genes,
probably resulting from the integration of ERBB2 and
ESR1 with the other genes composing the signature.
Remarkably, the predictive value of TRAR was inde-
pendent of ER status, evaluated both at the protein level
by immunohistochemistry, the standard measurement
approach in clinical practice and at ESR1 mRNA level
(as ER testing was not centralised in the NeoALTTO
trial). In addition, the predictive capability of TRAR
was independent of the proliferation score MSK, which
is consistently associated with pCR in patients treated
Fig. 4. Comparisons of the discriminatory capability between TRAR
and PAM50 classifier from the multivariate logistic regression
model including clinical variables in the TRAR cohort (n [ 226).
The receiver operating characteristic (ROC) curve derived from
the multivariate logistic model including PAM50 and the clinical
variables (i.e. treatment arm, oestrogen receptor status, age,
tumour size and lymph node status) is reported in red. The ROC
curve derived from the multivariate logistic model including
TRAR and the clinical variables is reported in blue and the ROC
curve derived from the multivariate logistic model including only
clinical variables is reported in grey.
Table 2
Association of the immune metagenes and MSK score with patho-
logical complete response within the two TRAR subgroups: univariate
logistic regression model.
Variables TRAR-low OR (95% CI) TRAR-high OR (95% CI)
HCK 2.65 (1.11;6.31) 0.96 (0.42;2.19)
IFN 1.10 (0.68;1.77) 0.79 (0.45;1.39)
LCK 1.69 (0.90;3.17) 0.98 (0.55;1.78)
MHC-II 1.94 (1.00;3.78) 1.00 (0.54;1.87)
MSK 3.15 (1.20;8.31) 1.94 (0.58;6.49)
STAT1 2.01 (1.13;3.60) 1.31 (0.75;2.28)
The bold values correspond to statistically significant odds ratio. The
Youden cut-off defines TRAR-low and TRAR-high cases.
OR, odds ratio; CI, confidence interval; HCK, haematopoietic cell
kinase, IFN, interferon; LCK, lymphocyte-specific kinase.
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chemotherapy.
As expected, and consistently with our previous ob-
servations [10], most of TRAR-low tumours belong to
the HER2-E subtype. Nevertheless, all subtypes could
be further subdivided into TRAR-low and TRAR-high,
indicating that TRAR may provide supplementary in-
formation to PAM50 subtypes. As a consequence,
TRAR may discriminate among patients with differen-
tial response to anti-HER2 therapies similarly or evenbetter than the molecular classifier PAM50.The predic-
tive value of TRAR for pCR was shown to be inde-
pendent of treatment arm. Despite the limitation of the
small sample size, this evidence supports the hypothesis
that TRAR might inform on the mechanisms of action
shared by different anti-HER2 agents, including but not
limited to inhibition of HER2 signalling and relevant in
mediating tumour response, i.e. induction and/or pro-
motion of ADCC, and tumour infiltration by T cells
[9,29,30].
In our study, immune signatures did not significantly
correlate with the likelihood of achieving a pCR after
anti-HER2 treatments, in contrast with the results from
others [31e33]. Differences between the trials, including
the type of HER2-targeted agent used (the tyrosine ki-
nase inhibitor L or the antibody P), the neoadjuvant
chemotherapy backbone (anthracyclines þ taxanes or
taxanes alone) and the methodological approaches
(platform used and immune signature tested) may have
accounted for discrepancies. Another potential expla-
nation is that the metagenes we tested probably provide
only partial information on the complexity of the
tumour-immune microenvironment and do not contain
the immune genes associated with pCR in our data set.
Nevertheless, in the TRAR-low subgroup, we found
both an enrichment in immune processes and an asso-
ciation between STAT1 and HCK signatures in patients
achieving pCR. Hence, our GO and KEGG findings
support the concept that preexisting immune activation
is a determinant of improved outcome in ERBB2 high/
ESR1 low HER2 positive BC, as TRAR-low cases are.
Indeed, our group has recently reported that infiltration
of cells of the innate immune system in the tumour
microenvironment of TRAR-low BC cases likely de-
pends on the activity of HER2 receptor and the lack of
ER inhibition on immune cell recruitment [34]. This
regulation might also explain why in TRAR-high BC
cases, which conversely are characterised by low
ERBB2/high ESR1 expression, immune signatures are
not predictive of pCR at all.
Our analyses have some limitations, which have to be
pointed out. The small patient population and the
retrospective nature of the study do not allow us to draw
any definitive conclusion about the effectiveness of the
TRAR classifier. In addition, the small sample size of
overall patient population and treatment arms
hampered any significant analysis of treatment interac-
tion and long-term outcome. However, this has not
prevented us from showing TRAR as a compelling
predictor of response to neoadjuvant anti-HER2-based
therapy.
Incorporating genomic profile into a larger patient
evaluation to better characterise not only primary
tumour but also host-tumour interplay is a must if one is
to overcome the limitations of predictive capability of
molecular classifiers [6,35]. Although confirmatory
studies on prospective independent case series are
S. Di Cosimo et al. / European Journal of Cancer 118 (2019) 1e9 7needed to evaluate the reproducibility of TRAR and its
possible integration with immune signatures or other
biomarkers including those derived from liquid biopsy,
the data presented support the development of TRAR
as a promising tool to identify responders to T as
monotherapy and to guide de-escalating therapy.Acknowledgements
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